Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (1-10 of 236) with videos related to

Pageof 24
Sort By:
Future Oncology (London, England)|February 18, 2011
Bevacizumab and its use in epithelial ovarian cancerUrsula A Matulonis
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
Management of newly diagnosed or recurrent ovarian cancerUrsula A Matulonis
Clinical Advances in Hematology & Oncology : H&O|August 25, 2017
Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: CommentaryUrsula A Matulonis
Gynecologic Oncology|December 9, 2022
The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome dataUrsula A Matulonis
Hematology/Oncology Clinics of North America|November 5, 2018
Ovarian CancerUrsula A Matulonis
Seminars in Oncology|April 28, 2004
End of life issues in older patientsUrsula A Matulonis
Oncology (Williston Park, N.Y.)|August 20, 2010
New advances in ovarian cancerJoyce Liu, Ursula A Matulonis
Hematology/Oncology Clinics of North America|January 17, 2012
New biologic agents for the treatment of gynecologic cancersNeil Horowitz, Ursula A Matulonis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advancesJoyce Liu, Ursula A Matulonis
Current Oncology Reports|October 14, 2011
Anti-angiogenic agents in ovarian cancer: dawn of a new era?Joyce Liu, Ursula A Matulonis
Pageof 24

Showing results (1-10 of 236) with videos related to

Sort By:
Pageof 24
Future Oncology (London, England)|February 18, 2011
Bevacizumab and its use in epithelial ovarian cancerUrsula A Matulonis
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
Management of newly diagnosed or recurrent ovarian cancerUrsula A Matulonis
Clinical Advances in Hematology & Oncology : H&O|August 25, 2017
Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: CommentaryUrsula A Matulonis
Gynecologic Oncology|December 9, 2022
The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome dataUrsula A Matulonis
Hematology/Oncology Clinics of North America|November 5, 2018
Ovarian CancerUrsula A Matulonis
Seminars in Oncology|April 28, 2004
End of life issues in older patientsUrsula A Matulonis
Oncology (Williston Park, N.Y.)|August 20, 2010
New advances in ovarian cancerJoyce Liu, Ursula A Matulonis
Hematology/Oncology Clinics of North America|January 17, 2012
New biologic agents for the treatment of gynecologic cancersNeil Horowitz, Ursula A Matulonis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advancesJoyce Liu, Ursula A Matulonis
Current Oncology Reports|October 14, 2011
Anti-angiogenic agents in ovarian cancer: dawn of a new era?Joyce Liu, Ursula A Matulonis
Pageof 24